<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069223</url>
  </required_header>
  <id_info>
    <org_study_id>21003</org_study_id>
    <nct_id>NCT02069223</nct_id>
  </id_info>
  <brief_title>Physiological Impact of Each Component of the Biliopancreatic Diversion With Duodenal Switch and Sleeve Gastrectomy</brief_title>
  <official_title>Physiological Impact of Each Component of the Biliopancreatic Diversion With Duodenal Switch and Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery procedures promote weight loss by limiting the amount of food consumed&#xD;
      through reduction of the size of the stomach and by decreasing absorption of nutrients&#xD;
      through reorganizing or bypassing portions of the small intestine. Among the procedures used&#xD;
      to induce weight loss, sleeve gastrectomy (SG) was initially developed in the early 90's as&#xD;
      the restrictive component of a biliopancreatic diversion with duodenal switch (BPD-DS). It&#xD;
      was then offered by laparoscopy as a staged-approach in order to reduce peri-operative&#xD;
      complications in high-risk patients. The second step of the surgery (i.e. the duodenal&#xD;
      switch) was planned when sufficient weight loss had been obtained. However, it was observed&#xD;
      that some patients experienced appreciable weight loss with the SG alone, and did not require&#xD;
      a second-stage surgery, thus avoiding the side-effects of a malabsorptive surgery. This led&#xD;
      to the surge in popularity of SG as a stand-alone operation, because of its relative&#xD;
      technical simplicity, feasibility, and good outcomes. Multiple mechanisms have been&#xD;
      postulated to induce metabolic recovery and weight loss following surgery. The independent&#xD;
      effects of each component of the BPD-DS with SG have never been investigated in humans within&#xD;
      a well-controlled study design. The general objective of the present project is to assess the&#xD;
      impact of each component of the BPD-DS and SG, either combined of separated, on physiological&#xD;
      variables potentially responsible for metabolic recovery. Patients will be randomized to&#xD;
      undergo one of three surgical sequences: 1) SG followed by BPD-DS one year later; 2) BPD-DS&#xD;
      followed by SG one year later; or 3) SG and BPD-DS within a single operation. A series of&#xD;
      tests will be performed at baseline, at 1 year, and 2 years after the initial surgery. We&#xD;
      propose two Specific Aims to asses 1) the impact of each surgical component on the hormonal&#xD;
      determinants of metabolic recovery; and 2) the impact of weight loss responses on&#xD;
      subcutaneous and visceral adipose tissue function improvements. This project will help better&#xD;
      understand the mechanisms underlying metabolic recovery following weight loss surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the changes in Satiety Levels and the changes in Incretin Levels</measure>
    <time_frame>Baseline, 12, 24 months</time_frame>
    <description>Satiety determination via questionnaires&#xD;
Incretin levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the changes of adipose tissue cells sizes and macrophage infiltration</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Adipose Tissue cell sizing&#xD;
Adipose Tissue macrophage infiltration via histology</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Biliopancreatic Diversion With Duodenal Switch</condition>
  <condition>Gastrectomy</condition>
  <arm_group>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPD-DS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrectomy+BPD-DS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy</intervention_name>
    <arm_group_label>BPD-DS</arm_group_label>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_label>Gastrectomy+BPD-DS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BPD-DS</intervention_name>
    <arm_group_label>BPD-DS</arm_group_label>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_label>Gastrectomy+BPD-DS</arm_group_label>
    <other_name>Biliopancreatic Diversion with Duodenal Switch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and Women between 18-60 years old;&#xD;
&#xD;
          -  BMI ≥ 45 à ≤ 55 kg/m2;&#xD;
&#xD;
          -  Subjects capable of understanding and being able to sign a consent form;&#xD;
&#xD;
          -  Subjects capable of following the protocol directives, including the proposed visits&#xD;
             (timeline);&#xD;
&#xD;
          -  Subjects living within a reasonable distance from the hospital and capable of being&#xD;
             present at all required visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women or women who plan on becoming pregnant during the study, or women in&#xD;
             fertile age range who refuse proper contraceptive methods during the study. (Must have&#xD;
             negative pregnancy test at the moment of enrollment and use medically acceptable&#xD;
             contraception which include: oral contraceptives, injectable or implantable&#xD;
             contraceptives, intrauterine devices or double-barrier method ie. condoms and&#xD;
             diaphragm);&#xD;
&#xD;
          -  Diabetics&#xD;
&#xD;
          -  Subjects with HbA1c ≥ 6,5 % or fasting Glucose ≥7mmol/l or non-fasting Glucose&#xD;
             ≥11mmol/l;&#xD;
&#xD;
          -  Previous oesophagal, gastric or bariatric surgery;&#xD;
&#xD;
          -  Irritable bowel syndrome, unexplained intermittent vomiting, severe abdominal pain,&#xD;
             diarrhea or chronic constipation;&#xD;
&#xD;
          -  History of duodenal or gastric ulcers;&#xD;
&#xD;
          -  Pre-operative hypoalbuminuria (&lt;35g/l);&#xD;
&#xD;
          -  History of renal disease, hepatic disease (cirrhosis) or severe cardiac or pulmonary&#xD;
             disease;&#xD;
&#xD;
          -  Corticosteroid intake in the previous month;&#xD;
&#xD;
          -  Presence of psychiatric problems or behavioral issues that could limit subject's&#xD;
             capacity at understanding the procedure and to conform to medical/surgical&#xD;
             recommendations;&#xD;
&#xD;
          -  History of drug use or alcoholism in previous 12 months before study;&#xD;
&#xD;
          -  History of inflammatory diseases of the gastro-intestinal tract (Esophagitis, varices,&#xD;
             gastric or duodenal ulcers, Crohn's disease, congenital or acquired anomalies of the&#xD;
             digestive tract).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Lapointe</last_name>
    <phone>4186568711</phone>
    <phone_ext>2136</phone_ext>
    <email>marc.lapointe@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélanie Nadeau</last_name>
    <phone>4186568711</phone>
    <phone_ext>3490</phone_ext>
    <email>melanie.nadeau@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRIUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Lapointe</last_name>
      <phone>4186568711</phone>
      <phone_ext>2136</phone_ext>
      <email>marc.lapointe@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>André Tchernof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Biertho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biliopancreatic Diversion with Duodenal Switch</keyword>
  <keyword>Gastrectomy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

